BIOSUPERIOR TECHNOLOGY, INC.

STTR Phase I: Bioengineering lung surfactant for the treatment of respiratory disease

BIOSUPERIOR TECHNOLOGY, INC. operates in chemistry of life processes based in LOS ALTOS, CA, founded in 2017.

Profile

The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase I project is to develop a synthetic lung surfactant product for the potential treatment of serious respiratory illnesses in neonatal patients. Bronchopulmonary dysplasia affects 10,000-15,000 pre-term infants per year and has a high mortality rate. Exposure of immature lung tissue to air results in inflammation and damages lungs and airways. Decreasing bronchopulmonary dysplasia is anticipated to reduce the number of days infants spend in the hospital, the need for supplemental oxygen, and other burdens on the healthcare system. The average length of stay in the neonatal intensive care unit for an infant with bronchopulmonary dysplasia is currently 103 days.

This Small Business Technology Transfer (STTR) Phase I project may result in the formulation of synthetic proteins for a bioengineered lung surfactant that contains full-length critical phospholipids and anti-inflammatory agents. Currently, bioengineered pulmonary surfactants are not as effective as animal-derived pulmonary surfactants for the treatment of illnesses related to bronchopulmonary dysplasia such as neonatal respiratory distress syndrome. The synthesis of full-length, native surfactant proteins has yet to be achieved. This research seeks to synthesize proteins which may add significant viscoelasticity to the pulm

Within the chemistry of life processes space, the company focuses on its core offering rather than a broad product line.

The business is associated with LOS ALTOS, CA.

The company is listed at the STTR Phase I stage of development.

The company reports a headcount in the 1-10 range.

Public records show total funding of about $256K.

Website: bio-superior.com